Business Wire

SES

Share
SES, ESA and European Commission Partnering to Deliver Satellite Quantum Cryptography System for European Cybersecurity

An SES-led consortium of 20 European companies, with the European Space Agency (ESA) and European Commission support, will design, develop, launch and operate the EAGLE-1 satellite-based end-to-end system for secure Quantum Key Distribution (QKD), enabling in-orbit validation and demonstration of next-generation cyber-security across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005427/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SES, ESA and European Commission Partnering to Deliver Satellite Quantum Cryptography System for European Cybersecurity (Graphic: Business Wire)

The groundbreaking partnership between ESA and an SES-led consortium, with the European Commission support, is advancing Europe to the front of space innovation with satellite-enabled QKD. Together with its European partners, SES will build the first sovereign European end-to-end space-based QKD system, developing and operating a dedicated low earth orbit (LEO) satellite and building a state-of-the-art QKD operations centre in Luxembourg. The project is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.

Using the EAGLE-1 system, ESA and the European Union Member States will achieve the first step to demonstrate and validate QKD technologies from low earth orbit to the ground. The EAGLE-1 project will provide valuable mission data for next generation Quantum Communication Infrastructures (QCIs), contributing for example to the EU plans to deploy a sovereign, autonomous cross-border quantum secure communications networks.

The EAGLE-1 satellite is due to launch in 2024 and will then complete three years of in-orbit mission supported by the European Commission. During this operational phase, the satellite will allow European Union governments and institutions as well as critical business sectors early access to long-distance QKD to path the way towards an EU constellation enabling ultra-secure data transmissions.

To implement the ultra-secure cryptographic key exchange system of EAGLE-1, the consortium will develop the QKD payload, terrestrial optical station, scalable quantum operational networks and key management system to interface with national QCIs.

Josef Aschbacher, ESA Director General, said, “European space innovation has gained strong momentum both from a technology perspective and in terms of commercialisation. It allows us to develop and implement next-generation, future-proof projects in space across critical domains like secure communication, next-generation networks and cybersecurity. Led by ESA, partially financed by the European Commission and implemented by SES, EAGLE-1 is a major step towards making the secure and scalable European Quantum Communications Infrastructure a reality.”

Elodie Viau, Director of Telecommunications and Integrated Applications at ESA, said, “In today’s increasingly interconnected world, keeping information secure is paramount. Robust encryption keys as well as technologies enabling their secure distribution are vital to this endeavour. We are proud to forge this partnership between ESA and a consortium led by SES to create the EAGLE-1 highly secure and autonomous quantum key distribution system. ESA enables the European space industry to succeed by federating industry around large-scale programmes, achieving competitive leaps forward.”

“European security and sovereignty in a future world of quantum computing is critical to the success of Europe and its Member States,” said Steve Collar, CEO of SES. “We are proud to leverage our multi-orbit credentials and our innovative platforms and solutions in partnership with ESA, the European Commission and the Luxembourg Government to advance quantum communications and implement the EAGLE-1 system, which is called to be a cornerstone for the development of secure and sovereign European networks of the future.”

For more information, visit the EAGLE-1 Newsroom

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >

Visit the Media Gallery >

About ESA

The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see www.esa.int

The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners. For more information, please visit our website: https://artes.esa.int/

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005427/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye